0001493152-23-002272.txt : 20230124 0001493152-23-002272.hdr.sgml : 20230124 20230124091513 ACCESSION NUMBER: 0001493152-23-002272 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230124 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230124 DATE AS OF CHANGE: 20230124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aesther Healthcare Acquisition Corp. CENTRAL INDEX KEY: 0001869974 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 871309280 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40793 FILM NUMBER: 23546056 BUSINESS ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 908-2658 MAIL ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 form8-k.htm
0001869974 false 0001869974 2023-01-24 2023-01-24 0001869974 AEHA:UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember 2023-01-24 2023-01-24 0001869974 AEHA:ClassOrdinaryShareParValue0.0001PerShareMember 2023-01-24 2023-01-24 0001869974 AEHA:WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member 2023-01-24 2023-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 24, 2023

 

Aesther Healthcare Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40793   87-1309280

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

515 Madison Avenue, 8th Floor – Suite 8078

New York, New York

   10022
(Address of principal executive offices)   (Zip Code)

 

(646) 908-2659

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant   AEHAU   The Nasdaq Stock Market LLC
Class A Ordinary Share, par value $0.0001 per share   AEHA   The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50   AEHAW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

As announced in a press release and related Current Report on Form 8-K dated August 31, 2022, Aesther Healthcare Acquisition Corp., a Delaware corporation (“Aesther”), entered into an Agreement and Plan of Merger by and among Aesther, Aesther Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Aesther (“Merger Sub”), Aesther Healthcare Sponsor, LLC, Aesther’s sponsor (the “Sponsor”), in its capacity as purchaser representative, Ocean Biomedical, Inc., a Delaware corporation (“Ocean Biomedical”), and Dr. Chirinjeev Kathuria, in his capacity as seller representative (as may be amended and/or restated from time to time, the “Merger Agreement”), pursuant to which, among other things, the parties will effect the merger of Merger Sub with and into Ocean Biomedical, with Ocean Biomedical continuing as the surviving entity (the “Merger”), as a result of which all of the issued and outstanding capital stock of Ocean Biomedical shall be exchanged for shares of Class A common stock, par value $0.0001 per share, of Aesther (the “Share Exchange”), subject to the conditions set forth in the Merger Agreement, with Ocean Biomedical surviving the Share Exchange as a wholly-owned subsidiary of Aesther (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the “Transaction”).

 

On January 24, 2023, Ocean Biomedical issued a press release announcing key company activities including upcoming important dates and events, notable investment activity, management comments, and information regarding Ocean Biomedical’s focus on three critical areas: oncology, pulmonary fibrosis, and malaria.

 

Exhibit 99.1 and the information set forth therein and herein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 8.01 Other Events.

 

The disclosure set forth above in Item 7.01 of this Current Report on Form 8-K is incorporated by reference herein.

 

Forward-Looking Statements

 

This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the proposed Transaction between Aesther and Ocean Biomedical, including without limitation statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied enterprise value, future financial condition and performance of Ocean Biomedical and the combined company after the closing and expected financial impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of Aesther’s public stockholders and the products and markets and expected future performance and market opportunities of Ocean Biomedical. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

 

2
 

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Aesther’s securities; (ii) the risk that the proposed Transaction may not be completed by Aesther’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the stockholders of Aesther, the satisfaction of the minimum net tangible assets and minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Aesther’s stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet The Nasdaq Global Market’s initial listing standards in connection with the consummation of the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Ocean Biomedical’s business relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations of Ocean Biomedical; (ix) the outcome of any legal proceedings that may be instituted against Ocean Biomedical or against Aesther related to the Merger Agreement or the proposed Transaction ; (x) changes in the markets in which Ocean Biomedical’s competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) risk that Ocean Biomedical may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Ocean Biomedical may not be able to develop and maintain effective internal controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Ocean Biomedical to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Ocean Biomedical may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Ocean Biomedical will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk that Ocean Biomedical, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Ocean Biomedical’s business; (xxii) the risk of cyber security or foreign exchange losses; (xxiii) the risk that Ocean Biomedical is unable to secure or protect its intellectual property; and (xxiv) those factors discussed in Aesther’s filings with the SEC and that are contained in the Definitive Proxy Statement relating to the proposed Transaction.

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in Aesther’s Annual Report on Form 10-K for the year ended December 31, 2021 and Aesther’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and which are described in the “Risk Factors” section of the Definitive Proxy Statement, and other documents to be filed by Aesther from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Ocean Biomedical and Aesther may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Aesther’s or Ocean Biomedical’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

3
 

 

Additional Information and Where to Find It

 

In connection with the Merger Agreement and the proposed transaction, Aesther has filed with the U.S. Securities and Exchange Commission (the “SEC”) a Definitive Proxy Statement on Schedule 14A relating to the proposed transaction. This communication is not intended to be, and is not, a substitute for the Definitive Proxy Statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed transaction. Aesther’s stockholders and other interested persons are advised to read the Definitive Proxy Statement and the amendments thereto, and documents incorporated by reference therein filed in connection with the proposed transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed transaction. The Definitive Proxy Statement and other relevant materials for the proposed transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire Definitive Proxy Statement and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the Definitive Proxy Statement and other documents filed with the SEC that will be incorporated by reference therein, without charge, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

 

Participants in the Solicitation

 

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including its most recent Annual Report on Form 10-K, the Definitive Proxy Statement, and other documents filed with the SEC.

 

No Offer or Solicitation

 

This press release is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release, dated January 24, 2023.
     
104   Cover Page Interactive Data File (embedded with the Inline XBRL)

 

4
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AESTHER HEALTHCARE ACQUISITION CORP.
     
  By: /s/ Suren Ajjarapu
  Name: Suren Ajjarapu
  Title: Chief Executive Officer

 

Date: January 24, 2023

 

5

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Logo Description automatically generated

 

Ocean Biomedical Provides Corporate Update and Company Summary

 

Ocean Biomedical stock is expected to trade on the Nasdaq Capital Market under ticker symbol “OCEA”

 

PROVIDENCE, RI and NEW YORK, January 24, 2023 – Ocean Biomedical (“Ocean”), a next-generation biopharma company, and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), a publicly traded special purpose acquisition company (SPAC), shared today an update on key company activities. Built on Ocean Biomedical’s expertise in technology transfer, a unique business model was created to bridge the ‘bench-to-bedside’ gap and accelerate the commercialization of novel assets from leading research universities and medical centers. Ocean Biomedical is expected to become a publicly traded company on NASDAQ under the symbols “OCEA” and “OCEAW” following the expected closing of a Business Combination with Aesther Corporation.

 

Key Upcoming Dates

 

Ocean Biomedical and Aesther would like to call attention to the following upcoming important dates and events:

 

●Shareholder vote: Friday, February 3, 2023
   
●Expected close of business combination between Ocean Biomedical and Aesther Healthcare Acquisition Corp: Tuesday, February 7, 2023
   
●Expected first day of trading on the Nasdaq Stock Exchange for Ocean Biomedical: Wednesday, February 8, 2023

 

Notable Investment Activity

 

Ocean and Aesther have partnered with some of the premier investment institutions in the health care space. This has led to a secure and growing runway to continue Ocean’s important innovations, with funding including:

 

●$123.9 million in past and ongoing grants, in use to enable first-in-class drug and vaccine candidates that make up Ocean’s initial core portfolio in oncology, fibrosis, and infectious disease, all based on new target discoveries
   
●A $40 million committed backstop by Vellar Opportunity Fund SPV LLC – Series 3
   
●A Common Stock Purchase Agreement with White Lion Capital LLC, which provides that White Lion Capital is committed to purchase the company’s Common Stock with an aggregate gross purchase price of up to $75 million

 

Pro forma enterprise value of the combined company is expected to be approximately $345 million, assuming no redemptions of current Aesther public stockholders.

 

Management Comments

 

“The scientific and operational progress Ocean Biomedical has had to date, even without access to the public markets, is astounding – the company is at an inflection point, with multiple ways to win. The combination of the company’s close ties to innovation coming out of the world’s top research institutions with the anticipated advantages of being a publicly-traded company would produce unprecedented value,” said Suren Ajjarapu, Chairman and CEO of Aesther. “With a world-class board and leadership team, Ocean’s trajectory is unmatched. This is a once-in-a-lifetime kind of company, and from an investment standpoint, is in a category of its own.”

 

“Ocean Biomedical acts as the parent of three distinct biotech companies and is ultimately responsible for a total of three platform assets and a diversified pipeline that addresses high-value and high-impact indications. Each of these assets are progressing towards the next stage of their development pipelines,” said Dr. Chirinjeev Kathuria, Ocean Biomedical co-founder and Executive Chairman of the Board of Directors. “Ocean has the vision and now, the tools, to concretely change the course of humanity for the better. First and foremost, our founders are dedicated to serving patients with some of the most devastating illnesses we face as humans today. That’s why we created Ocean Biomedical, which will be our most important legacy.”

 

 
 

 

Ocean Will Address Areas of Great Unmet Need Through Novel Scientific Breakthroughs

 

A key component of Ocean Biomedical’s model is to elevate the efforts of scientists at premier institutions such as Brown University, Harvard University, Yale University and Stanford University to ensure their discoveries advance through clinical development with urgency in order to reach the hands of doctors and patients who need them. Currently, the company’s portfolio is focused on three critical areas: oncology, pulmonary fibrosis, and infectious disease.

 

Oncology

 

●Non-small cell lung cancer (NSCLC) is the leading cause of cancer death and second most diagnosed cancer in the United States, affecting approximately 460,000 people in the U.S. alone.
   
●Glioblastoma multiforme (GBM) is a lethal type of brain tumor with a single-digit five-year survival rate. It affects approximately 28,000 people in the U.S. alone.

 

CHI3L1 is a novel target and pathway discovery, the master checkpoint inhibitor, uncovered by the Ocean team. This novel, bispecific antibody approach generates strong anti-tumor response in lung cancer and brain cancer, whether used in combination or as a monotherapy. Ocean Biomedical’s novel approach to tumor suppression, focused on controlling Chitinase 3-like-1 (CHI3LI), other immune checkpoint inhibitors, and T-cell co-stimulators, could control important pathways pan-cancer and has potential application for tumor suppression across multiple cancer pathways.

 

Pulmonary Fibrosis

 

●Idiopathic pulmonary fibrosis is a progressive disease that results in the irreversible loss of lung function with high morbidity and mortality rates. Its prevalence in the U.S. has been reported to range from 10-60 cases per 100,000 people, while in Europe it ranges from 1.3-32.5 cases per 100,000.
   
●Hermansky-Pudlak Syndrome (HPS) is a rare, genetic disease with high prevalence occurring in Puerto Rico, with 1 case every 1,800 people.

 

Ocean has identified a novel target and pathway discovery called Chitinase 1 (Chit1), as well as a potential inhibitor of this pathway called OCF-203. OCF-203 has been evaluated in multiple models of pulmonary fibrosis with impressive reductions in fibrosis. These discoveries hold potential for growth into other fibrotic diseases, including scleroderma, alcoholic liver disease, and NASH.

 

Malaria

 

●Malaria is a deadly disease with over 3 billion people at risk of infection annually worldwide. 200-300 million people are infected worldwide each year. It is the number one killer of children under five years old, with over 500,000 children under five killed each year.

 

Ocean’s proprietary platform for infectious diseases has yielded promising vaccine and therapeutic candidates for malaria, including the discovery of PfSEA-1 and PfGARP. These targets enable a promising new strategy for combating the disease. Moreover, the company’s drug target discovery platform has the potential to discover targets against other infectious diseases, like tuberculosis or another pandemic-type virus.

 

For more information, please visit www.oceanbiomedical.com. The company’s latest investor presentation as filed with the SEC can be found here.

 

 
 

 

Advisors

 

EF Hutton, division of Benchmark Investments, LLC, serves as capital markets advisor to Aesther Healthcare Acquisition Corp. Nelson Mullins Riley & Scarborough LLP serves as legal counsel to Aesther Healthcare Acquisition Corp. and Malone Bailey, LLP serves as auditors to Aesther Healthcare Acquisition Corp. Dykema Gossett PLLC serves as legal counsel to Ocean Biomedical, Inc. and Deloitte & Touche LLP serves as auditors to Ocean Biomedical, Inc.

 

About Ocean Biomedical

 

Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.

 

To learn more, visit www.oceanbiomedical.com

 

In August 2022, Ocean Biomedical entered a definitive merger agreement with Aesther Healthcare Acquisition Corp. (Nasdaq: AEHA), a special purpose acquisition company. Upon closing, the combined company is expected to change its name to Ocean Biomedical, Inc. and its Class A common stock is expected to be traded on the Nasdaq Capital Market under the symbol “OCEA.”

 

Forward-Looking Statements

 

This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the proposed Transaction between Aesther and Ocean Biomedical, including without limitation statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied enterprise value, future financial condition and performance of Ocean Biomedical and the combined company after the closing and expected financial impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of Aesther’s public stockholders and the products and markets and expected future performance and market opportunities of Ocean Biomedical. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

 

 
 

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Aesther’s securities; (ii) the risk that the proposed Transaction may not be completed by Aesther’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the stockholders of Aesther, the satisfaction of the minimum net tangible assets and minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Aesther’s stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet The Nasdaq Global Market’s initial listing standards in connection with the consummation of the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Ocean Biomedical’s business relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations of Ocean Biomedical; (ix) the outcome of any legal proceedings that may be instituted against Ocean Biomedical or against Aesther related to the Merger Agreement or the proposed Transaction ; (x) changes in the markets in which Ocean Biomedical’s competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) risk that Ocean Biomedical may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Ocean Biomedical may not be able to develop and maintain effective internal controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Ocean Biomedical to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Ocean Biomedical may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Ocean Biomedical will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk that Ocean Biomedical, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Ocean Biomedical’s business; (xxii) the risk of cyber security or foreign exchange losses; (xxiii) the risk that Ocean Biomedical is unable to secure or protect its intellectual property; and (xxiv) those factors discussed in Aesther’s filings with the SEC and that are contained in the definitive proxy statement relating to the proposed Transaction.

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in Aesther’s Annual Report on Form 10-K for the year ended December 31, 2021 and Aesther’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and which are described in the “Risk Factors” section of the definitive proxy statement, and other documents to be filed by Aesther from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Ocean Biomedical and Aesther may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Aesther’s or Ocean Biomedical’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

 
 

 

Additional Information and Where to Find It

 

In connection with the Merger Agreement and the proposed transaction, Aesther has filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement on Schedule 14A relating to the proposed transaction. This communication is not intended to be, and is not, a substitute for the definitive proxy statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed transaction. Aesther’s stockholders and other interested persons are advised to read the definitive proxy statement and the amendments thereto, and documents incorporated by reference therein filed in connection with the proposed transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed transaction. The definitive proxy statement and other relevant materials for the proposed transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire definitive proxy statement and definitive proxy statement, when it becomes available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the definitive proxy statement and other documents filed with the SEC that will be incorporated by reference therein, without charge, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

 

Participants in the Solicitation

 

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including its most recent Annual Report on Form 10-K, the definitive proxy statement, and other documents filed with the SEC.

 

No Offer or Solicitation

 

This press release is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

# # #

 

Investor Contact

 

IR@aestherhealthcarespac.com

 

Media Contact

 


Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end GRAPHIC 4 ex99-1_002.jpg begin 644 ex99-1_002.jpg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end EX-101.SCH 5 aeha-20230124.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 aeha-20230124_def.xml XBRL DEFINITION FILE EX-101.LAB 7 aeha-20230124_lab.xml XBRL LABEL FILE Class of Stock [Axis] Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant Class A Ordinary Share, par value $0.0001 per share Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 aeha-20230124_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 24, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 24, 2023
Entity File Number 001-40793
Entity Registrant Name Aesther Healthcare Acquisition Corp.
Entity Central Index Key 0001869974
Entity Tax Identification Number 87-1309280
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 515 Madison Avenue
Entity Address, Address Line Two 8th Floor – Suite 8078
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code (646)
Local Phone Number 908-2659
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant  
Title of 12(b) Security Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant
Trading Symbol AEHAU
Security Exchange Name NASDAQ
Class A Ordinary Share, par value $0.0001 per share  
Title of 12(b) Security Class A Ordinary Share, par value $0.0001 per share
Trading Symbol AEHA
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50  
Title of 12(b) Security Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50
Trading Symbol AEHAW
Security Exchange Name NASDAQ
XML 10 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001869974 2023-01-24 2023-01-24 0001869974 AEHA:UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember 2023-01-24 2023-01-24 0001869974 AEHA:ClassOrdinaryShareParValue0.0001PerShareMember 2023-01-24 2023-01-24 0001869974 AEHA:WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member 2023-01-24 2023-01-24 iso4217:USD shares iso4217:USD shares 0001869974 false 8-K 2023-01-24 Aesther Healthcare Acquisition Corp. DE 001-40793 87-1309280 515 Madison Avenue 8th Floor – Suite 8078 New York NY 10022 (646) 908-2659 true false false false Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant AEHAU NASDAQ Class A Ordinary Share, par value $0.0001 per share AEHA NASDAQ Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 AEHAW NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aestherhealthcarespac.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm aeha-20230124.xsd aeha-20230124_def.xml aeha-20230124_lab.xml aeha-20230124_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "aeha-20230124_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "aeha-20230124_lab.xml" ] }, "presentationLink": { "local": [ "aeha-20230124_pre.xml" ] }, "schema": { "local": [ "aeha-20230124.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 3, "memberStandard": 0, "nsprefix": "AEHA", "nsuri": "http://aestherhealthcarespac.com/20230124", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-01-24to2023-01-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aestherhealthcarespac.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-01-24to2023-01-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "AEHA_ClassOrdinaryShareParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Ordinary Share, par value $0.0001 per share" } } }, "localname": "ClassOrdinaryShareParValue0.0001PerShareMember", "nsuri": "http://aestherhealthcarespac.com/20230124", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "AEHA_UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant" } } }, "localname": "UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember", "nsuri": "http://aestherhealthcarespac.com/20230124", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "AEHA_WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50" } } }, "localname": "WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member", "nsuri": "http://aestherhealthcarespac.com/20230124", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001493152-23-002272-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-002272-xbrl.zip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end